1999
Human single-chain Fv immunoconjugates targeted to a melanoma-associated chondroitin sulfate proteoglycan mediate specific lysis of human melanoma cells by natural killer cells and complement
Wang B, Chen Y, Ayalon O, Bender J, Garen A. Human single-chain Fv immunoconjugates targeted to a melanoma-associated chondroitin sulfate proteoglycan mediate specific lysis of human melanoma cells by natural killer cells and complement. Proceedings Of The National Academy Of Sciences Of The United States Of America 1999, 96: 1627-1632. PMID: 9990075, PMCID: PMC15540, DOI: 10.1073/pnas.96.4.1627.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBase SequenceCell LineCells, CulturedCHO CellsChondroitin Sulfate ProteoglycansChromatography, LiquidComplement System ProteinsCricetinaeCytotoxicity, ImmunologicDrosophila melanogasterEndothelium, VascularHumansImmunoconjugatesImmunoglobulin FragmentsImmunoglobulin GImmunoglobulin Variable RegionKiller Cells, NaturalMass SpectrometryMelanomaMolecular Sequence DataRestriction MappingSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationTransfectionTumor Cells, CulturedConceptsHuman melanoma cellsNatural killer cellsNK cellsMelanoma cellsKiller cellsChondroitin sulfate proteoglycanCytolytic responsesMost human melanoma cellsTumor cellsVaccinated melanoma patientsCultured human melanoma cellsCytolytic immune responseFusion phage librarySpecific cytolytic responseMelanoma-associated chondroitin sulfate proteoglycanHuman single-chain FvSulfate proteoglycanMelanoma patientsSpecific lysisImmune responseMelanoma tumorsComplement cascadeTargeted tumor cellsImmunoconjugatesHuman IgG1
1993
Initiation of cardiac allograft rejection New developments in cellular and molecular mechanisms
Pfau S, Bender J. Initiation of cardiac allograft rejection New developments in cellular and molecular mechanisms. Trends In Cardiovascular Medicine 1993, 3: 196-203. PMID: 21244933, DOI: 10.1016/1050-1738(93)90006-r.Peer-Reviewed Original ResearchT cell activationEnd-stage heart diseaseEffective immunosuppressive therapyNatural killer lymphocytesImmune effector cellsViable therapeutic optionT lymphocyte recognitionT cell biologyEarly eventsCardiac transplantationImmunosuppressive therapyMedical complicationsEffector cellsTherapeutic optionsCytokine productionInflammatory cellsHeart diseaseKiller lymphocytesForeign antigensT cellsImmune responseClinical utilityVascular endotheliumRejection processLong-term success